Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -52.8 M.

Financial Results for Q2 2026

Cash Position

As of June 30, 2026, Odyssey Therapeutics, Inc. reported cash, cash equivalents, and marketable securities of $433.1 million, which is projected to fund operations into the second half of 2028.

Research and Development Expenses

Research and development expenses for the quarter ended June 30, 2026, totaled $36.2 million, an increase from $30.2 million in the same period of 2025, primarily due to higher external research and development costs for advancing clinical and preclinical programs.

General and Administrative Expenses

General and administrative expenses decreased to $10.5 million for the quarter ended June 30, 2026, compared to $13.2 million for the same period in 2025, mainly reflecting lower legal and accounting professional fees.

Net Loss

Odyssey Therapeutics, Inc. reported a net loss of - $52.8 million for the quarter ended June 30, 2026, which is higher than the net loss of - $41.2 million for the corresponding period in 2025.

Adjusted Net Loss (Non-GAAP)

Adjusted net loss (non-GAAP) was - $38.4 million for the quarter ended June 30, 2026, compared to - $38.1 million for the same period in 2025. The adjusted net loss for Q2 2026 excludes $8.7 million in non-cash charges related to the change in the fair value of contingent consideration and $5.7 million in stock-based compensation expense. For Q2 2025, it excluded - $0.6 million for change in fair value of contingent consideration and $3.7 million for stock-based compensation expense.

Operational Outlook and Milestones

Odyssey Therapeutics, Inc. anticipates presenting Phase 2a OD-001 data in October and initiating two new OD-001 trials in the second half of 2026, with topline data expected in the second half of 2027. For OD-002, the company plans to complete IND-enabling studies and file a CTA in the second half of 2026, targeting a Phase 1/2a trial initiation in the first half of 2027.